AGARWALEYE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 2.7
| Stock Code | AGARWALEYE | Market Cap | 14,108 Cr. | Current Price | 445 ₹ | High / Low | 568 ₹ |
| Stock P/E | 239 | Book Value | 61.8 ₹ | Dividend Yield | 0.00 % | ROCE | 5.94 % |
| ROE | 1.31 % | Face Value | 1.00 ₹ | DMA 50 | 444 ₹ | DMA 200 | 454 ₹ |
| Chg in FII Hold | -0.12 % | Chg in DII Hold | 0.05 % | PAT Qtr | 14.6 Cr. | PAT Prev Qtr | 4.95 Cr. |
| RSI | 53.0 | MACD | 3.07 | Volume | 83,880 | Avg Vol 1Wk | 68,682 |
| Low price | 327 ₹ | High price | 568 ₹ | PEG Ratio | 1.57 | Debt to equity | 0.30 |
| 52w Index | 49.0 % | Qtr Profit Var | 80.3 % | EPS | 1.75 ₹ | Industry PE | 47.1 |
📊 Agarwal Eye Hospital (AGARWALEYE) shows weak fundamentals despite its market cap of ₹14,108 Cr. ROE (1.31%) and ROCE (5.94%) are very low, reflecting poor efficiency. Debt-to-equity at 0.30 is manageable, but EPS of ₹1.75 is modest relative to valuation. Dividend yield is 0.00%, offering no income support. Quarterly PAT improved (4.95 Cr → 14.6 Cr, +80.3%), showing operational recovery, but overall profitability remains fragile. Valuation is severely stretched with P/E (239) compared to industry average (47.1), while PEG ratio (1.57) suggests growth is already priced in. Technicals show neutral momentum with RSI (53.0), MACD (3.07), and price trading near both 50 DMA (444 ₹) and 200 DMA (454 ₹).
🎯 Entry Zone: 430 ₹ – 445 ₹ (near DMA support)
📌 Long-Term Holding: Risky due to weak efficiency and extreme overvaluation. Suitable only for speculative exposure or short-term momentum trades. Long-term compounding potential is limited unless profitability improves significantly.
Positive
- Quarterly PAT growth (+80.3%) shows operational improvement.
- PEG ratio (1.57) indicates some growth-adjusted value.
- Price trading near DMA levels provides technical support.
- DII holdings increased (+0.05%), showing domestic institutional confidence.
Limitation
- Extremely high P/E (239) vs industry average (47.1).
- Very weak ROE (1.31%) and ROCE (5.94%).
- Dividend yield of 0.00% offers no income support.
- Decline in FII holdings (-0.12%) shows reduced foreign investor confidence.
- Low EPS (₹1.75) relative to valuation.
Company Negative News
- No major negative news reported; valuation and weak efficiency remain primary concerns.
Company Positive News
- Strong quarterly PAT recovery (+80.3%).
- DII inflows reflect domestic institutional support.
Industry
- Industry P/E (47.1) is far lower than AGARWALEYE’s 239, highlighting severe overvaluation.
- Healthcare/eyewear sector has steady demand but faces margin pressures.
Conclusion
⚠️ AGARWALEYE is financially stable with manageable debt but faces weak efficiency and severe overvaluation. Entry around 430–445 ₹ may suit speculative traders, but long-term investors should avoid until profitability stabilizes. Upside toward 460–480 ₹ possible in momentum trades, with strict stop-loss below 425 ₹.
This structured HTML report captures AGARWALEYE’s speculative momentum opportunity but highlights its weak fundamentals and severe valuation risks. If you’d like, I can extend this into a peer benchmarking overlay against other healthcare/eyewear companies to show relative positioning. Would you like me to prepare that next?